Silje Kvistad1, Kjell-Morten Myhr2, Trygve Holmøy3, Søren Bakke4, Antonie G Beiske5, Kristian S Bjerve6, Harald Hovdal7, Kristin I Løken-Amsrud8, Finn Lilleås9, Rune Midgard10, Gro Njølstad11, Tom Pedersen12, Jūratė Šaltytė Benth13, Stig Wergeland14, Oivind Torkildsen14. 1. Norwegian MS Competence Centre, Haukeland University Hospital, Jonas Lies vei 65, 5053 Bergen, Norway silje.agnethe.stokke@helse-bergen.no. 2. Norwegian MS Competence Centre, Haukeland University Hospital, Norway/KG Jebsen Center for MS Research, University of Bergen, Norway/Norwegian MS Registry and Biobank, Haukeland University Hospital, Norway. 3. Institute of Clinical Medicine, University of Oslo, Norway/Akershus University Hospital, Norway. 4. Oslo University Hospital, Norway. 5. MS Centre Hakadal, Norway. 6. St. Olav's Hospital, Trondheim University Hospital, Norway/Children's and Women's Health, Norwegian University of Science and Technology, Norway. 7. St Olav's Hospital, Trondheim University Hospital, Norway. 8. Institute of Clinical Medicine, University of Oslo, Norway/Innlandet Hospital Trust, Norway. 9. Curato Oslo, Norway. 10. Molde Hospital, Norway/Unit for Applied Clinical Research, Norwegian University of Science and Technology, Norway. 11. Haukeland University Hospital, Norway. 12. Unilabs Drammen, Norway. 13. Institute of Clinical Medicine, University of Oslo, Norway/Helse Sør-Øst Health Services Research Centre, Akershus University Hospital, Norway. 14. Norwegian MS Competence Centre, Haukeland University Hospital, Norway/KG Jebsen Center for MS Research, University of Bergen, Norway.
Abstract
BACKGROUND: Previous reports indicate an association between Epstein-Barr virus (EBV) antibody levels and multiple sclerosis (MS) disease activity, but the results have been conflicting. OBJECTIVES: The objective of this paper is to study if EBV antibody levels reflect MRI disease activity in MS and examine the potential for EBV antibody levels as biomarkers for treatment response. METHODS: A total of 87 MS patients were followed for two years prior to and during interferon beta (IFNB) treatment, with MRI examinations and serum measurement of IgM and IgG antibodies to viral capsid antigen (VCA), EBV nuclear antigen 1 (EBNA-1) and early antigen (EA). Associations between EBV antibody levels and MRI activity were assessed by a logistic regression model. RESULTS: Higher anti-EBNA-1 IgG levels were associated with increased MRI activity, OR = 2.95 (95% CI 1.07-8.10; p = 0.036) for combined unique activity (CUA; the sum of T1Gd+ lesions and new or enlarging T2 lesions). Although most patients were anti-VCA IgM negative, there was an inverse association, OR = 0.32 (95% CI 0.12-0.84; p = 0.021) with CUA during IFNB treatment. CONCLUSIONS: This study supports an association between anti-EBNA-1 IgG levels and MS disease activity. We also found an inverse association with anti-VCA IgM levels during IFNB treatment not previously described, indicating anti-VCA IgM as a possible biomarker for IFNB treatment response.
BACKGROUND: Previous reports indicate an association between Epstein-Barr virus (EBV) antibody levels and multiple sclerosis (MS) disease activity, but the results have been conflicting. OBJECTIVES: The objective of this paper is to study if EBV antibody levels reflect MRI disease activity in MS and examine the potential for EBV antibody levels as biomarkers for treatment response. METHODS: A total of 87 MS patients were followed for two years prior to and during interferon beta (IFNB) treatment, with MRI examinations and serum measurement of IgM and IgG antibodies to viral capsid antigen (VCA), EBV nuclear antigen 1 (EBNA-1) and early antigen (EA). Associations between EBV antibody levels and MRI activity were assessed by a logistic regression model. RESULTS: Higher anti-EBNA-1 IgG levels were associated with increased MRI activity, OR = 2.95 (95% CI 1.07-8.10; p = 0.036) for combined unique activity (CUA; the sum of T1Gd+ lesions and new or enlarging T2 lesions). Although most patients were anti-VCA IgM negative, there was an inverse association, OR = 0.32 (95% CI 0.12-0.84; p = 0.021) with CUA during IFNB treatment. CONCLUSIONS: This study supports an association between anti-EBNA-1 IgG levels and MS disease activity. We also found an inverse association with anti-VCA IgM levels during IFNB treatment not previously described, indicating anti-VCA IgM as a possible biomarker for IFNB treatment response.
Authors: Dejan Jakimovski; Murali Ramanathan; Bianca Weinstock-Guttman; Niels Bergsland; Deepa P Ramasamay; Ellen Carl; Michael G Dwyer; Robert Zivadinov Journal: Mult Scler Date: 2019-02-13 Impact factor: 6.312
Authors: Y F Wang; D D He; H W Liang; D Yang; H Yue; X M Zhang; R Wang; B Li; H X Yang; Y Liu; Y Chen; Y X Duan; C Y Zhang; X Chen; J Fu Journal: Clin Exp Immunol Date: 2017-03-28 Impact factor: 4.330
Authors: Marie Wunsch; Christopher Hohmann; Bianca Milles; Christina Rostermund; Paul V Lehmann; Michael Schroeter; Antonios Bayas; Jochen Ulzheimer; Mathias Mäurer; Süleyman Ergün; Stefanie Kuerten Journal: Viruses Date: 2016-04-23 Impact factor: 5.048